Arnold S H Chee, Andrew C Y Mak, Ka Wai Kam, Molly S C Li, Mary Ho, Marten E Brelen, Li Jia Chen, Wilson W K Yip, Alvin L Young
{"title":"表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌脉络膜转移的疗效:10年回顾","authors":"Arnold S H Chee, Andrew C Y Mak, Ka Wai Kam, Molly S C Li, Mary Ho, Marten E Brelen, Li Jia Chen, Wilson W K Yip, Alvin L Young","doi":"10.1097/IAE.0000000000004314","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/purpose: </strong>To describe the clinical characteristics of choroidal metastasis in patients with non-small-cell lung carcinoma and report treatment outcomes following targeted therapy versus conventional radiotherapy and/or chemotherapy.</p><p><strong>Methods: </strong>A retrospective review was conducted in 2 hospitals in Hong Kong between 2013 and 2023. Outcomes included tumor response and visual function following treatment.</p><p><strong>Results: </strong>A total of 25 eyes of 21 Chinese patients with choroidal metastasis secondary to metastatic non-small-cell lung carcinoma were identified. The majority of patients were nonsmokers. At the time of diagnosis, 88% of eyes were visually symptomatic with a mean visual acuity of 20/100. There were 52% of tumors locating within the macula. Tyrosine kinase inhibitor monotherapy, tyrosine kinase inhibitor with radiotherapy, and radiotherapy and/or chemotherapy groups were observed to demonstrate similar tumor response from 1 month and comparable ocular progression-free indices. Untreated patients had deteriorated vision without any tumor response. The tyrosine kinase inhibitor monotherapy group achieved the most rapid and differential vision gain than other groups.</p><p><strong>Conclusion: </strong>Tyrosine kinase inhibitor achieved durable disease control in epidermal growth factor receptor mutation-positive non-small-cell lung carcinoma patients with choroidal metastasis, while improving visual function. Tyrosine kinase inhibitor can be considered as an alternative to conventional orbital radiotherapy or chemotherapy for these patients in view of the rapid visual recovery.</p>","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":"207-214"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN TREATING CHOROIDAL METASTASIS FROM NON-SMALL-CELL LUNG CANCER: A 10-Year Review.\",\"authors\":\"Arnold S H Chee, Andrew C Y Mak, Ka Wai Kam, Molly S C Li, Mary Ho, Marten E Brelen, Li Jia Chen, Wilson W K Yip, Alvin L Young\",\"doi\":\"10.1097/IAE.0000000000004314\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/purpose: </strong>To describe the clinical characteristics of choroidal metastasis in patients with non-small-cell lung carcinoma and report treatment outcomes following targeted therapy versus conventional radiotherapy and/or chemotherapy.</p><p><strong>Methods: </strong>A retrospective review was conducted in 2 hospitals in Hong Kong between 2013 and 2023. Outcomes included tumor response and visual function following treatment.</p><p><strong>Results: </strong>A total of 25 eyes of 21 Chinese patients with choroidal metastasis secondary to metastatic non-small-cell lung carcinoma were identified. The majority of patients were nonsmokers. At the time of diagnosis, 88% of eyes were visually symptomatic with a mean visual acuity of 20/100. There were 52% of tumors locating within the macula. Tyrosine kinase inhibitor monotherapy, tyrosine kinase inhibitor with radiotherapy, and radiotherapy and/or chemotherapy groups were observed to demonstrate similar tumor response from 1 month and comparable ocular progression-free indices. Untreated patients had deteriorated vision without any tumor response. The tyrosine kinase inhibitor monotherapy group achieved the most rapid and differential vision gain than other groups.</p><p><strong>Conclusion: </strong>Tyrosine kinase inhibitor achieved durable disease control in epidermal growth factor receptor mutation-positive non-small-cell lung carcinoma patients with choroidal metastasis, while improving visual function. Tyrosine kinase inhibitor can be considered as an alternative to conventional orbital radiotherapy or chemotherapy for these patients in view of the rapid visual recovery.</p>\",\"PeriodicalId\":54486,\"journal\":{\"name\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"volume\":\" \",\"pages\":\"207-214\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Retina-The Journal of Retinal and Vitreous Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/IAE.0000000000004314\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004314","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:描述非小细胞肺癌(NSCLC)患者脉络膜转移瘤(CM)的临床特征,并报告靶向治疗与传统放疗和/或化疗的治疗效果:方法:2013-2023年间,在香港两家医院进行了一项回顾性研究。结果:21 位中国患者共 25 只眼睛接受了靶向治疗:结果:共发现了 21 名继发于转移性 NSCLC 的中国 CM 患者的 25 只眼睛。大多数患者不吸烟。确诊时,88%的患者无视觉症状,平均视力为20/100。52%的肿瘤位于黄斑区。据观察,TKI单药治疗组、TKI联合放疗组和放疗和/或化疗组从1个月起的肿瘤反应相似,眼部无进展指数也相当。未经治疗的患者视力恶化,但没有任何肿瘤反应。与其他组相比,酪氨酸激酶抑制剂(TKI)单药组的视力恢复最快,差异也最大:结论:对于表皮生长因子受体突变阳性的 NSCLC CM 患者,TKI 可实现持久的疾病控制,同时改善视功能。鉴于视力恢复迅速,TKI可被视为这些患者常规眼眶放疗或化疗的替代疗法。
EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN TREATING CHOROIDAL METASTASIS FROM NON-SMALL-CELL LUNG CANCER: A 10-Year Review.
Background/purpose: To describe the clinical characteristics of choroidal metastasis in patients with non-small-cell lung carcinoma and report treatment outcomes following targeted therapy versus conventional radiotherapy and/or chemotherapy.
Methods: A retrospective review was conducted in 2 hospitals in Hong Kong between 2013 and 2023. Outcomes included tumor response and visual function following treatment.
Results: A total of 25 eyes of 21 Chinese patients with choroidal metastasis secondary to metastatic non-small-cell lung carcinoma were identified. The majority of patients were nonsmokers. At the time of diagnosis, 88% of eyes were visually symptomatic with a mean visual acuity of 20/100. There were 52% of tumors locating within the macula. Tyrosine kinase inhibitor monotherapy, tyrosine kinase inhibitor with radiotherapy, and radiotherapy and/or chemotherapy groups were observed to demonstrate similar tumor response from 1 month and comparable ocular progression-free indices. Untreated patients had deteriorated vision without any tumor response. The tyrosine kinase inhibitor monotherapy group achieved the most rapid and differential vision gain than other groups.
Conclusion: Tyrosine kinase inhibitor achieved durable disease control in epidermal growth factor receptor mutation-positive non-small-cell lung carcinoma patients with choroidal metastasis, while improving visual function. Tyrosine kinase inhibitor can be considered as an alternative to conventional orbital radiotherapy or chemotherapy for these patients in view of the rapid visual recovery.
期刊介绍:
RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice.
In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color.
Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.